Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 226

1.

A double-masked, randomized study to investigate the safety and efficacy of daclizumab to treat the ocular complications related to Behçet's disease.

Buggage RR, Levy-Clarke G, Sen HN, Ursea R, Srivastava SK, Suhler EB, Altemare C, Velez G, Ragheb J, Chan CC, Nussenblatt RB, Bamji AT, Sran P, Waldmann T, Thompson DJ.

Ocul Immunol Inflamm. 2007 Mar-Apr;15(2):63-70.

2.

Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis: a multicenter noncomparative interventional case series.

Nussenblatt RB, Peterson JS, Foster CS, Rao NA, See RF, Letko E, Buggage RR.

Ophthalmology. 2005 May;112(5):764-70.

PMID:
15878055
3.

Infliximab treatment for ocular and extraocular manifestations of Behçet's disease.

Accorinti M, Pirraglia MP, Paroli MP, Priori R, Conti F, Pivetti-Pezzi P.

Jpn J Ophthalmol. 2007 May-Jun;51(3):191-6. Epub 2007 Jun 7.

PMID:
17554481
4.

Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Behcet's disease on infliximab therapy.

Keino H, Okada AA, Watanabe T, Taki W.

Br J Ophthalmol. 2011 Sep;95(9):1245-50. doi: 10.1136/bjo.2010.194464. Epub 2010 Dec 22.

PMID:
21183514
5.

Intravenous daclizumab for recalcitrant ocular inflammatory disease.

Bhat P, Castañeda-Cervantes RA, Doctor PP, Foster CS.

Graefes Arch Clin Exp Ophthalmol. 2009 May;247(5):687-92. doi: 10.1007/s00417-009-1043-4. Epub 2009 Feb 6.

PMID:
19198869
6.

Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta.

Wynn D, Kaufman M, Montalban X, Vollmer T, Simon J, Elkins J, O'Neill G, Neyer L, Sheridan J, Wang C, Fong A, Rose JW; CHOICE investigators..

Lancet Neurol. 2010 Apr;9(4):381-90. doi: 10.1016/S1474-4422(10)70033-8. Epub 2010 Feb 15. Erratum in: Lancet Neurol. 2010 Aug;9(8):759. Wadinger, K [corrected to Wandinger, K].

PMID:
20163990
7.

Daclizumab, a humanised monoclonal antibody to the interleukin 2 receptor (CD25), for the treatment of moderately to severely active ulcerative colitis: a randomised, double blind, placebo controlled, dose ranging trial.

Van Assche G, Sandborn WJ, Feagan BG, Salzberg BA, Silvers D, Monroe PS, Pandak WM, Anderson FH, Valentine JF, Wild GE, Geenen DJ, Sprague R, Targan SR, Rutgeerts P, Vexler V, Young D, Shames RS.

Gut. 2006 Nov;55(11):1568-74. Epub 2006 Apr 7.

8.

Secukinumab in the treatment of noninfectious uveitis: results of three randomized, controlled clinical trials.

Dick AD, Tugal-Tutkun I, Foster S, Zierhut M, Melissa Liew SH, Bezlyak V, Androudi S.

Ophthalmology. 2013 Apr;120(4):777-87. doi: 10.1016/j.ophtha.2012.09.040. Epub 2013 Jan 3.

PMID:
23290985
9.

Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis.

Bielekova B, Howard T, Packer AN, Richert N, Blevins G, Ohayon J, Waldmann TA, McFarland HF, Martin R.

Arch Neurol. 2009 Apr;66(4):483-9. doi: 10.1001/archneurol.2009.50.

10.

Reduction of acute renal allograft rejection by daclizumab. Daclizumab Double Therapy Study Group.

Nashan B, Light S, Hardie IR, Lin A, Johnson JR.

Transplantation. 1999 Jan 15;67(1):110-5.

PMID:
9921806
11.

High-dose daclizumab for the treatment of juvenile idiopathic arthritis-associated active anterior uveitis.

Sen HN, Levy-Clarke G, Faia LJ, Li Z, Yeh S, Barron KS, Ryan JG, Hammel K, Nussenblatt RB.

Am J Ophthalmol. 2009 Nov;148(5):696-703.e1. doi: 10.1016/j.ajo.2009.06.003. Epub 2009 Aug 6.

12.

Humanized anti-interleukin-2 (IL-2) receptor alpha therapy: long-term results in uveitis patients and preliminary safety and activity data for establishing parameters for subcutaneous administration.

Nussenblatt RB, Thompson DJ, Li Z, Chan CC, Peterson JS, Robinson RR, Shames RS, Nagarajan S, Tang MT, Mailman M, Velez G, Roy C, Levy-Clarke GA, Suhler EB, Djalilian A, Sen HN, Al-Khatib S, Ursea R, Srivastava S, Bamji A, Mellow S, Sran P, Waldmann TA, Buggage RR.

J Autoimmun. 2003 Nov;21(3):283-93. Erratum in: J Autoimmun. 2004 Aug;23(1):93.

PMID:
14599854
13.

Anti-TNF-α therapy in patients with refractory uveitis due to Behçet's disease: a 1-year follow-up study of 124 patients.

Calvo-Río V, Blanco R, Beltrán E, Sánchez-Bursón J, Mesquida M, Adán A, Hernandez MV, Hernandez Garfella M, Valls Pascual E, Martínez-Costa L, Sellas-Fernández A, Cordero Coma M, Díaz-Llopis M, Gallego R, Salom D, García Serrano JL, Ortego N, Herreras JM, Fonollosa A, García-Aparicio AM, Maíz O, Blanco A, Torre I, Fernández-Espartero C, Jovani V, Peiteado-Lopez D, Pato E, Cruz J, Fernández-Cid C, Aurrecoechea E, García M, Caracuel MA, Montilla C, Atanes A, Hernandez FF, Insua S, González-Suárez S, Sánchez-Andrade A, Gamero F, Linares L, Romero-Bueno F, García AJ, Almodovar R, Minguez E, Carrasco Cubero C, Olive A, Vázquez J, Ruiz Moreno O, Jiménez-Zorzo F, Manero J, Muñoz Fernández S, Rueda-Gotor J, González-Gay MA.

Rheumatology (Oxford). 2014 Dec;53(12):2223-31. doi: 10.1093/rheumatology/keu266. Epub 2014 Jul 4.

PMID:
24996907
14.

Long-term safety and efficacy of infliximab therapy in refractory uveitis due to Behçet's disease.

Abu El-Asrar AM, Abboud EB, Aldibhi H, Al-Arfaj A.

Int Ophthalmol. 2005 Jun;26(3):83-92. Epub 2006 Sep 23.

PMID:
17031510
15.

High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, non-infectious uveitis.

Yeh S, Wroblewski K, Buggage R, Li Z, Kurup SK, Sen HN, Dahr S, Sran P, Reed GF, Robinson R, Ragheb JA, Waldmann TA, Nussenblatt RB.

J Autoimmun. 2008 Sep;31(2):91-7. doi: 10.1016/j.jaut.2008.05.001. Epub 2008 Jun 20.

16.
17.

Daclizumab to prevent rejection after cardiac transplantation.

Hershberger RE, Starling RC, Eisen HJ, Bergh CH, Kormos RL, Love RB, Van Bakel A, Gordon RD, Popat R, Cockey L, Mamelok RD.

N Engl J Med. 2005 Jun 30;352(26):2705-13.

18.

Clinical features of chinese patients with Behçet's disease.

Yang P, Fang W, Meng Q, Ren Y, Xing L, Kijlstra A.

Ophthalmology. 2008 Feb;115(2):312-318.e4. Epub 2007 Aug 10.

PMID:
17692378
19.

Safety and Efficacy of Gevokizumab in Patients with Behçet's Disease Uveitis: Results of an Exploratory Phase 2 Study.

Tugal-Tutkun I Md, Kadayifcilar S Md, Khairallah M Md, Lee SC Md PhD, Ozdal P, Özyazgan Y, Song JH Md, Yu HG Md PhD, Lehner V PhD, de Cordoue A Md, Bernard O Md, Gül A Md.

Ocul Immunol Inflamm. 2017 Feb;25(1):62-70. doi: 10.3109/09273948.2015.1092558. Epub 2016 Jan 30.

PMID:
26829647
20.

Long-term efficacy of infliximab on background vascular leakage in patients with Behçet's disease.

Keino H, Okada AA, Watanabe T, Taki W.

Eye (Lond). 2014 Sep;28(9):1100-6. doi: 10.1038/eye.2014.138. Epub 2014 Jun 20.

Supplemental Content

Support Center